Drug Interactions with Amiodarone
Amiodarone has critical, potentially life-threatening drug interactions that require mandatory dose adjustments for warfarin (reduce by 33-50%), digoxin (reduce by 50%), and simvastatin (limit to ≤20 mg daily), with close monitoring essential due to amiodarone's potent inhibition of multiple CYP450 enzymes and P-glycoprotein. 1, 2
Mechanism of Interactions
Amiodarone is a potent inhibitor of multiple metabolic pathways 2:
- CYP3A4 (irreversibly and weakly for amiodarone; competitively and potently for its metabolite desethylamiodarone)
- CYP2C9 (metabolizes warfarin)
- CYP2D6 (metabolizes beta blockers and narcotics)
- CYP1A2
- P-glycoprotein (reversibly inhibited)
This broad inhibition profile means amiodarone affects numerous commonly prescribed cardiovascular medications, with interactions persisting for weeks to months after discontinuation due to its extremely long half-life 2.
Critical Drug Interactions Requiring Dose Adjustment
Warfarin - HIGHEST PRIORITY
- Reduce warfarin dose by one-third to one-half when starting amiodarone
- Monitor PT/INR at least weekly for the first 6 weeks of combined therapy
- Peak interaction effects occur at 7 weeks after initiation
- Amiodarone reduces warfarin clearance, causing sudden and pronounced increases in PT/INR that can result in serious or fatal bleeding
Digoxin - HIGHEST PRIORITY
- Reduce digoxin dose by 50% when starting amiodarone
- Digoxin levels predictably double after coadministration
- Monitor digoxin levels closely and watch for clinical signs of toxicity
- Mechanism: inhibition of P-glycoprotein membrane transporter system, blocking digoxin secretion from renal tubules
Statins - CRITICAL FOR MYOPATHY/RHABDOMYOLYSIS RISK
Simvastatin: 3
- Limit simvastatin to ≤20 mg daily when combined with amiodarone (FDA-mandated dose restriction from 2002)
- Amiodarone increases simvastatin exposure by approximately 75%
- In the SEARCH trial: 8 cases of myopathy and 7 cases of rhabdomyolysis occurred with simvastatin 80 mg + amiodarone versus zero cases with simvastatin 20 mg (relative risk 8.8)
- This combination has resulted in deaths
Lovastatin: 3
- Limit to ≤40 mg daily when combined with amiodarone
Preferred statins with amiodarone: 3
- Rosuvastatin, atorvastatin, pitavastatin, fluvastatin, or pravastatin are reasonable choices
- These have no significant pharmacokinetic interaction with amiodarone
- No dose adjustment required
Other Cardiovascular Drugs
Beta-blockers and Calcium Channel Blockers: 2
- Use with extreme caution due to additive effects
- Risk of symptomatic bradycardia, sinus arrest, and AV block
- May require pacemaker insertion in severe cases
- Not primarily a pharmacokinetic interaction but pharmacodynamic (additive effects)
Cyclosporine: 2
- Produces persistently elevated cyclosporine levels
- Results in elevated creatinine despite cyclosporine dose reduction
- Requires close monitoring and dose adjustment
Drugs That Increase Amiodarone Levels
Protease Inhibitors: 2
- Inhibit CYP3A4, increasing amiodarone concentrations
- Monitor for amiodarone toxicity with serial serum concentration measurements
Cimetidine: 2
- Inhibits CYP3A4, can increase serum amiodarone levels
- Increases amiodarone AUC by 50% and Cmax by 84%
- Grapefruit juice should NOT be consumed during amiodarone treatment
Drugs That Decrease Amiodarone Levels
Rifampin: 2
- Potent CYP3A4 inducer
- Decreases serum concentrations of both amiodarone and desethylamiodarone
St. John's Wort: 2
- Induces CYP3A4
- May result in reduced amiodarone levels
Drugs With QT Prolongation Risk
Avoid or use extreme caution with: 2
- Fluoroquinolones (e.g., levofloxacin, moxifloxacin)
- Macrolide antibiotics (e.g., erythromycin, azithromycin)
- Azole antifungals
- Loratadine (QT prolongation and torsades de pointes reported)
- Trazodone (QT prolongation and torsades de pointes reported)
These combinations increase risk of torsades de pointes.
Other Antiarrhythmic Drugs
Management: 2
- Initiate other antiarrhythmics at approximately half the usual recommended dose
- Reduce doses of previously administered agents by 30-50% several days after adding amiodarone
- Reserve combination therapy for life-threatening ventricular arrhythmias incompletely responsive to single agents
- Monitor carefully for conduction disturbances and arrhythmia exacerbation
Anesthetic Interactions
General Anesthesia: 2
- Patients may be more sensitive to myocardial depressant and conduction effects of halogenated inhalational anesthetics
- Risk of hypotension and atropine-resistant bradycardia
- Close perioperative monitoring mandatory
Local Anesthesia: 2
- Sinus bradycardia reported with lidocaine
- Seizures associated with increased lidocaine concentrations when combined with IV amiodarone
Monitoring Protocol for Drug Interactions
Baseline before starting amiodarone: 1
- Digoxin level (if taking digoxin)
- PT/INR (if taking warfarin)
- Complete medication review for all potential interactions
During warfarin therapy: 1
- PT/INR monitoring at least weekly during first 6 weeks
During digoxin therapy: 1
- Monitor digoxin levels after dose reduction
- Watch for clinical signs of toxicity
Every 6 months: 1
- Digoxin level (if taking digoxin)
Common Pitfalls to Avoid
Failing to reduce warfarin and digoxin doses prophylactically - these interactions are predictable and dose adjustments should be made immediately when starting amiodarone, not after toxicity develops
Prescribing simvastatin >20 mg daily with amiodarone - this is an FDA-mandated dose restriction based on mortality data
Not warning patients about grapefruit juice - this significantly increases amiodarone levels
Forgetting about interactions after stopping amiodarone - due to its extremely long half-life (weeks to months), interactions persist long after discontinuation
Adding other QT-prolonging drugs without considering cumulative risk - amiodarone already prolongs QT interval in nearly all patients
Inadequate monitoring frequency for warfarin - weekly INR checks for 6 weeks are mandatory, not optional